RJA
XBI icon

Raymond James & Associates’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Raymond James & Associates’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$1.11M Buy
+11,100
New +$1.09M ﹤0.01% 2631
2024
Q2 		– Sell
-5,600
Closed -$493K – 4094
2024
Q1 		$493K Buy
+5,600
New +$520K ﹤0.01% 3068

Other funds holding XBI

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Raymond James & Associates's XBI Position: Q3 2024 in Review

Raymond James & Associates increased its State Street SPDR S&P Biotech ETF (XBI) stake by 7.7% in Q3 2024, buying an estimated $2.7M and bringing the position to 383,355 shares worth $37.9M. The position accounts for 0.02% of the portfolio, ranked #543.

Raymond James & Associates first reported a position in XBI in Q2 2013 and has held it in 46 quarters since. The position peaked at $46.5M in Q3 2018. 769 funds tracked by Wall St. Rank hold XBI as of Q3 2024.

  • Raymond James & Associates held 383,355 shares of State Street SPDR S&P Biotech ETF worth $37.9M as of Q3 2024.
  • Raymond James & Associates bought 27,511 State Street SPDR S&P Biotech ETF shares in Q3 2024, an estimated $2.7M.
  • State Street SPDR S&P Biotech ETF made up 0.02% of Raymond James & Associates's portfolio in Q3 2024, its #543 holding.
  • Raymond James & Associates first reported a position in State Street SPDR S&P Biotech ETF in Q2 2013 and has held it in 46 quarters since.
  • Raymond James & Associates's State Street SPDR S&P Biotech ETF position peaked at $46.5M in Q3 2018.
  • 769 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.